Please ensure Javascript is enabled for purposes of website accessibility

Trulieve Stock Falls on Q4 Results

By Eric Volkman - Updated Mar 23, 2021 at 6:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Net profit wasn't nearly as high as it was in previous periods.

Trulieve Cannabis (TCNNF 2.78%), one of the better-respected marijuana stocks, didn't get a lot of love from investors on Tuesday after reporting fourth-quarter and full-year 2020 earnings.

For the quarter, the Florida-based operator took in $168.4 million in revenue, more than double the nearly $80 million it earned in the same period last year, and 24% higher than the third quarter.

Atypically profitable for a marijuana company, Trulieve had net income of $3 million in the quarter. But this was down from both the year-ago profit of $12.2 million and the preceding quarter's $17.4 million. On the basis of the profitability metric favored by weed companies, Trulieve did well in adjusted EBITDA. That line item was $78.2 million in the fourth quarter, versus the year-ago $43.8 million and the third quarter's $65.8 million.

Marijuana leaf held up against the sky.

Image source: Getty Images.

The top-line improvement was due in no small measure to a larger retail footprint. In the quarter alone, Trulieve opened 11 new dispensaries, bringing its total to 75. Most of these are in Florida, Trulieve's home and stronghold, although the company continues to spread across the U.S. In 2020, it was set to enter its sixth state when it obtained four dispensary permits and a processor license in West Virginia.

Its growth momentum should continue; the company proffered guidance of $815 million to $850 million in revenue for 2021, which would represent a year-over-year improvement of at least 56%. Adjusted EBITDA is forecast to rise by a minimum of 41% to a range of $355 million to $375 million.

Those projections are encouraging, but investors might have been dismayed by those notable net profit declines. Trulieve's stock closed nearly 3.5% lower on Tuesday, against the S&P 500's slip of only 0.8%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trulieve Cannabis Stock Quote
Trulieve Cannabis
TCNNF
$15.16 (2.78%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.